137 related articles for article (PubMed ID: 11328664)
1. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine.
Tamai I; Kido Y; Yamashita J; Sai Y; Tsuji A
J Drug Target; 2000; 8(6):383-93. PubMed ID: 11328664
[TBL] [Abstract][Full Text] [Related]
2. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.
Murata M; Tamai I; Kato H; Nagata O; Tsuji A
J Pharmacol Exp Ther; 1999 Jul; 290(1):51-7. PubMed ID: 10381759
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys.
Matsuda M; Sakashita M; Mizuki Y; Yamaguchi T; Fujii T; Sekine Y
Arzneimittelforschung; 1994 Jan; 44(1):55-9. PubMed ID: 7907872
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
6. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier.
Ishiguro N; Nozawa T; Tsujihata A; Saito A; Kishimoto W; Yokoyama K; Yotsumoto T; Sakai K; Igarashi T; Tamai I
Drug Metab Dispos; 2004 May; 32(5):519-24. PubMed ID: 15100174
[TBL] [Abstract][Full Text] [Related]
7. Studies on the first-pass metabolism of ebastine in rats.
Fujii T; Matsumoto S; Hatoyama T; Miyazaki H
Arzneimittelforschung; 1997 Aug; 47(8):949-53. PubMed ID: 9296281
[TBL] [Abstract][Full Text] [Related]
8. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
Rohatagi S; Gillen M; Aubeneau M; Jan C; Pandit B; Jensen BK; Rhodes G
Int J Clin Pharmacol Ther; 2001 Mar; 39(3):126-34. PubMed ID: 11396753
[TBL] [Abstract][Full Text] [Related]
9. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants.
Shon JH; Yeo CW; Liu KH; Lee SS; Cha IJ; Shin JG
J Clin Pharmacol; 2010 Feb; 50(2):195-204. PubMed ID: 19841159
[TBL] [Abstract][Full Text] [Related]
10. P glycoprotein regulated transport of glutamate at blood brain barrier.
Liu XD; Liu GQ
Acta Pharmacol Sin; 2001 Feb; 22(2):111-6. PubMed ID: 11741514
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
12. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.
Liu KH; Kim MG; Lee DJ; Yoon YJ; Kim MJ; Shon JH; Choi CS; Choi YK; Desta Z; Shin JG
Drug Metab Dispos; 2006 Nov; 34(11):1793-7. PubMed ID: 16896065
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects.
Huang MY; Argenti D; Wilson J; Garcia J; Heald D
Am J Ther; 1998 May; 5(3):153-8. PubMed ID: 10099053
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein restricted transport of nimodipine across blood-brain barrier.
Zhang L; Liu XD; Xie L; Wang GJ
Acta Pharmacol Sin; 2003 Sep; 24(9):903-6. PubMed ID: 12956939
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of ebastine in children.
Simons FE; Watson WT; Simons KJ
J Pediatr; 1993 Apr; 122(4):641-6. PubMed ID: 8096545
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
Noveck RJ; Preston RA; Swan SK
Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
[TBL] [Abstract][Full Text] [Related]
18. mRna expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting.
Hosoya KI; Takashima T; Tetsuka K; Nagura T; Ohtsuki S; Takanaga H; Ueda M; Yanai N; Obinata M; Terasaki T
J Drug Target; 2000; 8(6):357-70. PubMed ID: 11328662
[TBL] [Abstract][Full Text] [Related]
19. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine.
Van Rooij J; Schoemaker HC; Bruno R; Reinhoudt JF; Breimer DD; Cohen AF
Br J Clin Pharmacol; 1993 Jun; 35(6):661-3. PubMed ID: 8101096
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.
Vincent J; Liminana R; Meredith PA; Reid JL
Br J Clin Pharmacol; 1988 Nov; 26(5):497-502. PubMed ID: 2905150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
